Table 1.
Recipient characteristics stratified by achievement of a textbook outcome (TO).
| Characteristica | Achieved TO N = 245 (44%) |
Failed TO N = 312 (56%) |
P-value |
|---|---|---|---|
| Age (years) | 52 (43–62) | 54 (44–62) | 0.4 |
| Sex | <0.01 | ||
| Female | 123 (50%) | 116 (37%) | |
| Male | 122 (50%) | 196 (63%) | |
| Race | 0.013 | ||
| White | 124 (51%) | 116 (37%) | |
| Black | 107 (44%) | 173 (55%) | |
| Asian | 4 (2%) | 4 (1%) | |
| Other | 10 (4%) | 19 (6%) | |
| Ethnicity (Hispanic) | 6 (2%) | 12 (4%) | 0.4 |
| Body mass index (kg/m2) | 28.9 (24.8–33.0) | 28.6 (24.6–33.2) | 0.8 |
| Panel reactive antibody at transplant (%)b | |||
| Class I | 0 (0–13) | 0 (0–12) | 0.8 |
| Missing | 0 (0%) | 0 (0%) | |
| Class II | 0 (0–0) | 0 (0–0) | 0.8 |
| Missing | 0 (0%) | 1 (0.3%) | |
| Etiology of kidney disease | 0.6 | ||
| Alport syndrome | 4 (2%) | 4 (1%) | |
| Calcineurin inhibitor nephrotoxicity | 11 (5%) | 14 (5%) | |
| Chronic glomerulonephritis | 11 (5%) | 11 (4%) | |
| Chronic nephrosclerosis | 1 (0.4%) | 1 (0.3%) | |
| Congenital obstructive uropathy | 8 (3%) | 6 (2%) | |
| Focal glomerular sclerosis | 28 (11%) | 25 (8%) | |
| HIV nephropathy | 2 (0.8%) | 2 (0.6%) | |
| Hypertensive nephrosclerosis | 45 (18%) | 54 (17%) | |
| IgA nephropathy | 18 (7%) | 15 (5%) | |
| Lithium toxicity | 3 (1%) | 0 (0%) | |
| Malignant hypertension | 3 (1%) | 5 (2%) | |
| Nephrolithiasis | 3 (1%) | 0 (0%) | |
| Polycystic kidney disease | 21 (9%) | 32 (10%) | |
| Renal cell carcinoma | 1 (0.4%) | 1 (0.3%) | |
| Sickle cell anemia | 2 (0.8%) | 2 (0.6%) | |
| Systemic lupus erythematosus | 9 (4%) | 12 (4%) | |
| Type 1 diabetes mellitus | 7 (3%) | 13 (4%) | |
| Type 2 diabetes mellitus | 48 (20%) | 82 (26%) | |
| Vasculitis | 1 (0.4%) | 3 (1%) | |
| Other | 19 (8%) | 29 (9%) | |
| History of prior transplant | 37 (15%) | 46 (15%) | 0.9 |
| Kidney | 29 (12%) | 38 (12%) | 0.9 |
| Liver | 3 (1%) | 4 (1%) | >0.9 |
| Lung | 2 (0.8%) | 3 (1%) | >0.9 |
| Heart | 4 (2%) | 3 (1%) | 0.7 |
| History of diabetes | 80 (33%) | 124 (40%) | 0.08 |
| Estimated Post-Transplant Survival Score (%) | 36 (16–58) | 46 (24–72) | <0.01 |
| Pre-transplant dialysis | 178 (73%) | 273 (88%) | <0.01 |
| Dialysis duration (years) | 2.54 (1.27–4.20) | 3.83 (1.99–5.75) | <0.01 |
| Induction immunosuppression | <0.01 | ||
| Basiliximab | 38 (16%) | 72 (23%) | |
| Anti-thymocyte globulin | 89 (36%) | 114 (37%) | |
| Campath | 28 (11%) | 17 (5%) | |
| High-dose corticosteroids | 67 (27%) | 91 (29%) | |
| Other | 12 (5%) | 13 (4%) | |
| None | 11 (5%) | 4 (1%) | |
| Missing | 0 (0%) | 1 (0.3%) | |
| Initial maintenance immunosuppression | |||
| Tacrolimus | 216 (88%) | 284 (91%) | 0.3 |
| Cyclosporine | 1 (0.4%) | 3 (1%) | 0.6 |
| Mycophenolate mofetil | 213 (87%) | 286 (92%) | 0.07 |
| Azathioprine | 2 (0.8%) | 1 (0.3%) | 0.6 |
| Sirolimus | 27 (11%) | 20 (6%) | 0.052 |
| Belatacept | 30 (12%) | 22 (7%) | 0.04 |
| Corticosteroids | 217 (89%) | 289 (93%) | 0.1 |
| Other | 1 (0.4%) | 2 (0.6%) | >0.9 |
a
Presented as median (interquartile range) for continuous variables and frequency (proportion) for categorical variables.
b
Most recent pre-transplant panel reactive antibody levels.